Shares of Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $6.70 and traded as high as $9.00. Hemispherx BioPharma shares last traded at $6.70, with a volume of 7,639 shares trading hands.
Hemispherx BioPharma Price Performance
The stock’s 50 day moving average price is $6.70 and its two-hundred day moving average price is $6.70.
About Hemispherx BioPharma
Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) is a U.S.-based biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of viral infections, cancers and immune system disorders. The company’s research centers on harnessing the body’s innate immune response to address diseases that currently lack broadly effective treatments.
Hemispherx’s principal commercial product is Alferon N Injection, an antiviral drug indicated for the treatment of external genital warts.
Read More
- Five stocks we like better than Hemispherx BioPharma
- Trump’s AI Secret: 100X Faster Than Nvidia
- Do not delete, read immediately
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Wall Street Alert: Buy AES
- NEW LAW: Congress Approves Setup For Digital Dollar?
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
